Our previous work involved the development of a recombinant fowlpox virus encoding survivin (FP-surv) vaccine that was evaluated for efficacy in mesothelioma mouse models. Results showed that FP-surv vaccination generated significant immune responses, which led to delayed tumor growth and improved animal survival. We have extended those previous findings in the current study, which involves the pre-clinical development of an optimized version of FP-surv designed for human immunization 
INTRODUCTION
Despite recent progress in surgical, chemotherapeutic, and radiotherapy approaches, colon, lung, brain, and breast. [6] [7] [8] Expression of survivin is typically limited to developing tissues but becomes reactivated in adult tissues during the neoplastic transformation, contributing to apoptosis evasion and molecular pathways driving unrestricted proliferation and angiogenesis in tumor cells. 9 Survivin expression is a marker of poor prognosis and/or resistance to therapy in multiple cancers. 10 In patients with a variety of cancers, survivin-specific cell mediated and humoral immune responses have been
shown. [11] [12] [13] [14] Preclinical and clinical data from survivin vaccination studies suggest that these vaccines can induce immune responses and do not raise substantial safety concerns. Multiple HLA class I-binding peptides and one HLA class II-binding peptide of survivin have been identified, some of which have demonstrated immunogenicity in clinical trials. 15, 16 Malignant mesothelioma (MM) is an aggressive and deadly cancer. It originates from a chronic inflammatory process arising from asbestos or erionite exposure. The median patient survival is 9-12 months from diagnosis and intervention with trimodality therapy (chemotherapy, surgical resection and thoracic radiation) only extends survival by an average of 5 months. Survivin overexpression has been reported in MM in different studies. 17, 18 Our previous work involved the development of a novel recombinant fowlpox virus encoding survivin (FP-surv) vaccine that was evaluated for efficacy in different MM mouse models. Mice were injected subcutaneously or intraperitoneally with murine fiber-induced MM tumor cells and vaccinated with FP-surv. Results showed that FP-surv vaccination generated significant immune responses in both models, which led to delayed tumor growth and improved animal survival.
We have extended those previous findings in the current study, which involves the preclinical development of an optimized version of FP-surv designed for human immunization (HIvax). With the purpose of identifying survivin-derived peptides that are highly immunogenic for the most common HLAs in the human population, the survivin protein was analyzed using an innovative epitope-prediction algorithm called EpiMatrix. [19] [20] [21] [22] The immunogenicity of the predicted peptides was confirmed in coculture experiments using autologous DC and T cells isolated from human healthy donors. The sequences encoding peptides, confirmed to induce CTLs activation in these co-cultures, were then inserted in a transgene optimized for presentation of processed peptides on MHC-I (HIvax1 
RESULTS

In silico epitope mapping and peptide selection
The human survivin protein was computationally screened for class I and class II MHC epitopes using EpiMatrix. The protein sequence was parsed into 9-mer sequences, each overlapping the next by 8 amino acids, respectively, for a total of 134 9-mers. Each of these peptides was then scored for Class I HLA motif matches to the A*0101, A*0201, A*0301, A*2402, B*0702 and B*4403 alleles. More than 50 EpiMatrix hits (Zscore > 1.64; top 5% of scores) were discovered (data not shown). Among these, 4
sequences, positively scored for the considered alleles, were selected for experimental validation (Supplemental table 1 ). For Class II, epitope dense regions containing sequences predicted to bind multiple Class II HLA alleles (DRB1*0101, *0301, *0401, *0701, *1101, *1301 and *1501) were also identified. Three of these regions containing "hits" for several analyzed alleles were selected and the resulting peptide sequences were synthesized for experimental validation (Supplemental table 2 ).
Human survivin-derived peptides induce activation of primary human CD3 + T cells
Seven peptides (Hsurv1-7) representing sequences considered immunogenic in a major number of alleles were synthesized (Table 1) . These EpiMatrix predicted peptides were used to prime human DC from naïve healthy donors. Autologous T cells were cocultured with the DC for a 2 wks period, followed by reactivation with DC loaded with the same peptide in the presence of monensin, to allow evaluation of IFN production. All peptides but one (Hsurv4) stimulated a significant number of specific IFN + CD3 + T lymphocytes in the donors (Figure 1 Fig.1 ). These results suggested that the T cell IFN responses were elicited by the peptides themselves.
Removal of survivin 20-28 peptide (Hsurv4) from stimulatory peptides leads to stronger and more consistent in vitro immunization
The survivin peptide 20-28, designed Hsurv4 in our experiments, was the only peptide selected from the EpiMatrix analysis that did not induce significant CD3 + T cell overall responses in our population of naïve human donors. This 9-mer was predicted to bind to multiple MHC-I alleles, but it only induced CD8 + T cell activation from one human subject out of ten. To better evaluate the contribution of Hsurv4 in a hypothetical setting of multi-antigen vaccination, we compared pools of survivin peptides containing Hsurv4 (Hsurv1-7) to those without it (Hsurv 1,2,3,5,6,7). DC were stimulated with these peptide pools and used to prime autologous T cells. Fig.2 ). These results, together with those obtained using the single Hsurv4 peptide, suggest that the exclusion of this epitope may produce better immunization responses in humans.
Development of HIvax1 and HIvax2 and analysis of their expression in human primary DC
We constructed two fowlpox-based DNA vaccines, HIvax1 and HIvax2, each containing a distinct set of HLA class I and class II epitopes ( Figure 3A ). In HIvax1, sequences encoding Hsurv5, 6 and 7 were engineered into the vaccine matching the same order in which they are presented in the wild-type protein. Spacer sequences (Ala-Ala-Tyr) were included to promote the interaction between epitopes and transporters of antigen processing (TAP) that facilitate MHC-I loading in the endoplasmic reticulum (ER). 25 To further guide the HIvax1 encoded polypeptides to the ER and facilitate MHC-I loading, the immunoglobulin K (IgK) leader sequence was positioned upstream of epitope sequences, 26 resulting in trafficking of the peptide-MHC-I complex to the cell surface for interaction with the T cell receptor (TCR) on CD8 + T cells ( Figure 3D ). In designing the HIvax2 antigen we included the tissue plasminogen activator (tPA) leader sequence upstream of epitope sequences to direct translation products to the secretory pathway.
The inclusion of Gly-Pro-Gly-Pro-Gly spacers between peptides, avoids the formation of immunodominant junctional epitopes. 27 In both HIvax1 and HIvax2, V5 tag sequences were included at the C-terminus to facilitate polypeptides detection. 
RT-PCR was
In vitro immunization of human DC with HIvax1 or HIvax2 induces IFN production in autologous T cells
The efficacy of HIvax vaccines in stimulating survivin specific T cells was evaluated using immune cells from two naïve healthy donors with different haplotypes ( 
T cells activated by HIvax1 and HIvax2 exhibit cytotoxic activity towards MM cells
In previous studies we demonstrated that human malignant mesothelioma (MM) cells express high levels of survivin. 17 To further evaluate the efficacy of our HIvax approach, experiments were conducted in which survivin overexpressing ADA MM cells were co- In designing HIvax1, MHC-I peptides were separated by Ala-Ala-Tyr spacers and targeted to the ER by including an IgK signal sequence. This strategy drives the correct presentation of 9-mer peptides in the groove of MHC-I and has been successfully used in several vaccine studies. 25, 31 For HIvax2, epitopes were instead separated by GlyPro-Gly-Pro-Gly spacers and fused with a plasminogen activator signal sequence (tPA)
to promote their presentation on MHC-II. Expression of the HIvax2 transgene should result in a polypeptide that is secreted, subsequently re-engulfed, and degraded through exogenous antigen processing pathways within lysosomes. Resultant peptides are loaded into the grooves of MHC-II and transported to the plasma membrane for presentation to CD4 + T cells. In addition, the HIvax2 peptides may be also be loaded into MHC-I through cross-presentation pathways. 21, 22 In brief, prematurely truncated or abnormally folded proteins are exported to the cytosol, processed by the proteasome and resultant peptides loaded on MHC-I in the ER (Fig. 3) . This pathway may also be involved in presentation of HIvax1 epitopes to MHC-II as previously demonstrated.
32-34
The synthetic transgenes used in this study were cloned in recombinant FP vectors.
Vaccines based on recombinant vectors like FP induce a strong inflammatory response, directed mainly towards the vector-encoded proteins. Pox viral vectors are among the most heavily exploited in vaccine development, 17 and FP has shown particularly promising results as a vaccine for infectious diseases and cancer. 35 FP infection leads to effective antigen presentation by human antigen presenting cells, and the generation of antigen-specific CTLs. 36 An advantage of FP for vaccination is the fact that this virus does not productively replicate in mammalian cells, but still leads to effective expression of epitopes as supported by the current study. 
MATERIALS AND METHODS
Epitope selection and peptide synthesis
Survivin epitopes were scored for binding affinity, across a range of common HLA, using the EpiMatrix algorithm. 37 Top-scoring sequences were synthesized as 9 mer peptides for presentation on MHC-I, and as 15-18 mer for MHC-II (Table I) 
61-80) for MHC-II.
Mesothelioma cell line and primary cells
The human MM cell line ADA was characterized and generously provided by Dr. H. 
In vitro immunization and human T cell cultures.
To generate monocyte-derived dendritic cells (DC) from PBMCs, adherent cells were cultured for 7 days in X-VIVO 15 (Lonza, #04-744Q) containing 500 units/mL recombinant human interleukin 4 (IL-4) and 1,000 units/mL recombinant human granulocyte macrophage colony-stimulating factor (GM-CSF) (both from BioLegend, Events registering above this threshold value in peptide-stimulated samples were considered "positive" and indicated in data tables as "+" (> background); or "++" (two times > background); or "+++", (three times > background).
HIvax vaccines engineering
Epitope sequences were concatenated to form two multi-epitope genes: HIvax1, containing HLA Class I epitopes, and HIvax2, containing HLA Class II epitopes (Fig. 3A) .
All the peptides encoded by these two DNA vaccines were identified by immunoinformatics methods and their immunogenicity confirmed with the in vitro immunization experiments described above. To avoid creation of novel epitopes at epitope junctions, an algorithm which iteratively re-orders epitopes to reduce junctional immunogenicity (VaccineCAD), was used to optimize epitope order 21 . In addition, where re-ordering by VaccineCAD did not sufficiently reduce potential junctional immunogenicity, spacer sequences (Ala-Ala-Tyr for HIvax1, and Gly-Pro-Gly-Pro-Gly for HIvax2) were engineered between some epitopes to optimize antigen presentation. A Kozak sequence was positioned upstream of the coding sequence for efficient translation initiation. In HIvax1, to target the peptides to the MHC-I processing pathway, the immunoglobulin K (IgK) leader sequence (MGWSCIILFLVATATGVHS) was placed upstream of epitope sequences. In HIvax2, to target the immunogens to the MHC-II processing pathway, the tissue plasminogen activator (tPA) leader sequence (MQMSPALTCLVLGLALVFGEGSA) was placed upstream of epitope sequences to direct translation products to the secretory pathway. A V5 tag was incorporated downstream of both epitope sequences followed by two stop codons. Genes were synthesized by GeneScript (Piscataway, NJ) and cloned into a cassette coding for enhanced GFP (eGFP) in the fowlpox Transfer Plasmid Green (TPG) 39, 40 . Two recombinant fowlpox vectors, expressing the two transgenes, were then generated as described previously. hours. Beads were then recovered, prepared and individually sequenced using 454 GS Junior sequencing system (Roche).
Immunofluorescence
Sequencing reads were de-multiplexed by sample and trimmed from the adaptor, MID, and primer sequences using the Integroomer application (http://courge.ics.hawaii.edu/inte/groomer/). The resulting sequences were then subtyped through local alignments against the HLA database 41 using the USERCH program.
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Granzyme B ELISPOT assay
To measure T cell cytotoxic ability, granzyme B secretion was analyzed using the Human Granzyme B ELISpot Kit (R&D system, #EL2906). 
Statistical analyses
For each blood donor, two experiments have been conducted with each condition analyzed in triplicate. All statistical tests were performed using GraphPad Prism (GraphPad, La Jolla, CA). Means of two groups were compared using two-tailed 
